Stockscreener 앱 받기
143.75
0.45%
0.64
전일 마감가:
$143.11
열려 있는:
$142.92
하루 거래량:
1.90M
Relative Volume:
1.00
시가총액:
$273.23B
수익:
$54.66B
순이익/손실:
$13.58B
주가수익비율:
20.49
EPS:
7.0171
순현금흐름:
$16.05B
1주 성능:
+1.95%
1개월 성능:
+4.56%
6개월 성능:
-7.29%
1년 성능:
+9.68%
1일 변동 폭
$142.80
$143.96
1주일 범위
$139.31
$144.28
52주 변동 폭
$121.57
$170.46
노바티스 ADR Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
143.75 | 273.23B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,179.27 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 630.04B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 488.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 359.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
노바티스 ADR Stock (NVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-10 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2026-09-09 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2026-09-09 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-03-11 | 업그레이드 | Argus | Hold → Buy |
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2026-01-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-12-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-09-12 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-08-08 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-02-12 | 개시 | Morgan Stanley | Underweight |
| 2025-02-04 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-12-04 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-09-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-09-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-09-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-19 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-23 | 개시 | BMO Capital Markets | Market Perform |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-09-25 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-03-27 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2023-01-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-12-05 | 업그레이드 | Stifel | Hold → Buy |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-05-09 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 재개 | Citigroup | Buy |
| 2021-12-14 | 다운그레이드 | Redburn | Buy → Neutral |
| 2021-12-06 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 개시 | Bernstein | Mkt Perform |
| 2021-03-10 | 다운그레이드 | Argus | Buy → Hold |
| 2021-02-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2020-09-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-03-10 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-04-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-04-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-10 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2018-05-25 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 재확인 | Leerink Partners | Outperform |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 개시 | Liberum | Buy |
모두보기
노바티스 ADR 주식(NVS)의 최신 뉴스
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - The Globe and Mail
Swiss Market Index Retreats; Novartis Shares Decline - marketscreener.com
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - Zacks Investment Research
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - PR Newswire
Novartis wins FDA approval for a form of chronic hives - marketscreener.com
AI companies run virtual drug trials, aim to improve success of human studies - Reuters
Novartis AG (CEUX:1NOVNM) Cyclically Adjusted Price-to-FCF : (As of Oct. 07, 2026) - GuruFocus
US FDA expands use of Novartis drug for chronic skin condition - Reuters
Why Is Novartis Stock Trading Higher Today?Novartis (NYSE:NVS) - Benzinga
Novartis (NVS) Secures FDA Approval for Rhapsido, Expanding Trea - GuruFocus
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU) - The Manila Times
Novartis Rhapsido® (remibrutinib) receives FDA approval as - GlobeNewswire
Novartis to Present Key Data on Multiple Sclerosis - marketscreener.com
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 - marketscreener.com
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 - GlobeNewswire Inc.
Novartis advances multiple sclerosis innovation with - GlobeNewswire
The patient who changed the course of my career - Novartis
Novartis AG (SWX: NOVN): Now September Has Ended, Is It Now Time To Buy? - Stocks Down Under
Novartis Sues Apotex Over Mekinist Copies, Tafinlar Drug Combo - Bloomberg Law News
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal - Zacks Investment Research
Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026 - GlobeNewswire Inc.
BofA Expects Higher Q3 Sales From Novartis Amid Strong Key Growth Drivers - Moomoo
Should You Invest in the VanEck Pharmaceutical ETF (PPH)? - Zacks Investment Research
Total non-current liabilities of Novartis AG – BX:NOT - TradingView
NOVARTIS AG N (NOTA.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Zacks Investment Research
Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity - GlobeNewswire Inc.
Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion - Bloomberg.com
Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights - GlobeNewswire Inc.
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Novartis faces securities fraud probe after dru... - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - prnewswire.com
Novartis AG : Receives a Sell rating from Goldman Sachs - marketscreener.com
Novartis Falls as Investors Continue to Digest September Trial Setbacks - Quiver Quantitative
Novartis AG (CEUX:1NOVNm) Stock Price & 30 Year Financial Data - GuruFocus
Community health takes a village: from Pulpit to Pew - Novartis
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities - GlobeNewswire Inc.
Gross margin % of Novartis AG Sponsored ADR – HAN:NOTA - TradingView
Net margin % of Novartis AG Sponsored ADR – HAN:NOTA - TradingView
Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors - GuruFocus
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis AG : Deutsche Bank reiterates its Neutral rating - marketscreener.com
Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure? - Yahoo Finance
Novartis AG Stock Warning Signs - GuruFocus
Novartis AG Hired Firms, 2003 - OpenSecrets
Novartis AG Lobbyists, 1998 - OpenSecrets
Novartis AG Agencies, 2026 - OpenSecrets
Novartis AG Lobbyists, 2026 - OpenSecrets
Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile - ChartMill
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover? - Yahoo Finance
노바티스 ADR (NVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
노바티스 ADR 주식 (NVS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Marshall Fiona | Officer |
Feb 12 '26 |
Proposed Sale |
161.35 |
30,743 |
4,960,277 |
0 |
| Bulto Carulla Victor | Officer |
Feb 09 '26 |
Proposed Sale |
156.21 |
7,500 |
1,171,576 |
0 |
0.26%
자본화:
|
볼륨(24시간):